C-reactive protein (CRP) has a prognostic role in cardiovascular and pulmonary diseases. Recent data suggest its pro-inflammatory effects in atherosclerotic lesion formation. This raises the hypothesis of whether or not CRP has pro-inflammatory effects on pulmonary vasculature by inducing the production of endothelin-l (ET)-l, a potent vasoconstrictor and proliferative cytokine, and expression of adhesion molecules which could culminate in inflammatory cell recruitment and vascular injury. Human pulmonary artery endothelial cells (HPAECs) were cultured and incubated with 25ptg/ml of human recombinant CRP and with interleukin (IL)-lP 10ng/ml, a well-known activator of endothelial cells, which served as a positive control for 24 hours. Expression of vascular cell adhesion molecule (VCAM)-l and intercellular adhesion molecule (ICAM)-l was assessed by flow cytometry. Secretion of ET-l from HPAECs was also evaluated. In this study we show that incubation of HPAECs with human recombinant CRP for 24 hours induced a significant increase in ICAM-l expression (from 610 to 6553 mean fluorescence intensity, p < 0.005) and VCAM-l expression (from 212 to 303 mean fluorescence intensity, p < 0.05), as compared to control. Adhesion molecule induction was similar to that observed in endothelial cells activated with IL-lp. Likewise, CRP potentiated the ET-l production by HPAECs. The levels of ET-l were significantly higher at 24 hours (controI19.94±3 vs CRP 46.54±18 pg/ml, p < 0.05).
heart failure and death (I, 2) . It is a dynamic and progressive disease arising from the combination of endothelial dysfunction and inflammation (I, 3) . Endothelial dysfunction leads to chronically impaired production of vasodilators such as nitric oxide (NO) and prostacyclin along with prolonged overexpression of vasoconstrictors such as endothelin-l (ET)-l. These effects lead to changes in vascular tone and vascular remodeling (4) .
Inflammatory processes are prominent in various subtypes of human and experimental pulmonary arterial hypertension (PAH) and are increasingly recognized as one of the major pathogenic components of pulmonary vascular remodeling (5) . Elevated circulating levels of the pro-inflammatory cytokines, interleukin (IL)-1 and IL-6 are correlated with the pulmonary vascular resistance in patients with PAH (l, 6) . Lung histology has also revealed inflammatory infiltrates in the form of plexiform lesions in patients displaying severe idiopathic pulmonary arterial hypertension (IPAH) and PAH related to connective tissue diseases (1).
The inflammatory process heightens the production of biomarkers such as C-reactive protein (CRP). CRP which is a prototypic marker of inflammation, has prognostic role in cardiovascular and pulmonary diseases (1, 6, 7) . Recent data suggest that human recombinant CRP, at concentrations known to predict vascular disease, elicits a multitude of effects on systemic vasculature, favoring a proinflammatory and pro-atherosclerotic phenotype (8) .
Mechanisms of CRP-induced endothelial dysfunction and activation of systemic vasculature include inhibition ofendothelial nitric oxide synthase (eNOS), increasing ET-l, cell adhesion molecules, plasminogen activator (PAI)-l, monocyteendothelial adhesion and monocyte chemotactic protein (MCP)-l levels (9) (10) (11) (12) (13) (14) (15) . These systemic data propose an investigation into a possible role for CRP in inflammatory cascade in the pulmonary vasculature.
We therefore hypothesize that CRP actively participates in the pulmonary vascular remodeling by mediating endothelial activation and dysfunction. The aim of this study is to assess the effects of CRP on the expression of adhesion molecules and ET-l secretion by human pulmonary artery endothelial cells (HPAECs) in vitro.
MATERIALS AND METHODS
An in-vitro study was conducted on HPAECs, to determine the effect of human recombinant CRP on the cell surface expression of adhesion molecule intercellular adhesion molecule (I CAM)-l and vascular cell adhesion molecule (VCAM)-I and ET-I secretion. HPAEC were treated with media alone, IL-I~(1Ong/ml, positive control), and CRP (25/-!g/ml) for 24 hours.
Reagents
HPAECs isolated from normal human pulmonary arteries and cell culture-reagents optimized for HPAEC culture, including endothelial cell medium (ECM), cell freezing medium, trypsin/EDTA solution, trypsin neutralization solution and trypan blue 0.4% were obtained from ScienCell Research Laboratories (Carlsbad, CA, USA). Fetal Bovine Serum (FBS) was obtained from Atlanta Biologicals (Lawrenceville, GA, USA). Highly purified human recombinant CRP was purchased from Calbiochem, EMD Chemicals (Gibbstown, NJ, USA). Human recombinat IL-I~, monoclonal fluorescence conjugated anti-CD 54 (PE-conjugated) and anti-CD 106 (FITC-conjugated) antibodies and their isotype control antibodies were purchased from BD Biosciences (San Jose, CA, USA). IL-I~was received as a lyophilized solution with bovine serum albumin (BSA). Reconstituted stock solution was prepared by adding ECM and 0.5-1mg/ ml of BSA, aliquoted and stored at -80°C. Commercial enzyme linked immunoassay kit for measuring ET-I was purchased from ARP American Research Products Inc, Belmont, MA, USA. Phosphate buffer saline solution (137 mM naCI, 2.7 mM KCI, 10 mM Na 2HP04 at pH 7.4) was prepared from reagents purchased from Sigma-Aldrich (St. Louis, MO). Cell culture plasticware was from USA Scientific (Orlando, FL, USA).
Culture ofendothelial cells
Human pulmonary artery endothelial cells were grown in ECM supplemented with 10% FBS, streptomycin (100/-!g/ml) and penicillin (100U/ml). Cells were cultured in 10 ern-culture dishes for 48 h in a 37°C incubator with 5% CO 2 , Confluent monolayers were detached with 0.1% trypsin/EDTA solution. Cell viability was tested using trypan blue solution. Cell viability exceeded 95% via the trypan blue exclusion test. For all experiments, HPAECs were used between three and five passages.
Cell adhesion molecule expression
HPAECs were seeded at a density of 2 x 10 5 cells per well in ECM supplemented with 10% FBS, streptomycin (100/-!g/ml) and penicillin (IOOU/ml), in three 6 well plates. Media was changed after 24 h. At 48 h, the media was changed a second time and at that point the cells were treated with 251lg!ml of human recombinant CRP, lOng! ml of IL-l~(positive control), or control media solution for 24 h. For detecting intercellular adhesion molecule [ICAM-I, (CD 54)] and vascular cell adhesion molecule [VCAM-I, (CD 106)], the endothelial cells were detached with 0.1% trypsin/EDTA for one minute, centrifuged and then resuspended in PBS buffer containing 0.5% BSA and 2 mM EDTA at pH 8.0. Cells were then incubated with monoclonal fluorescence conjugated anti-CD 54 (PE-conjugated) and anti-CD 106 (FITC-conjugated) antibodies at 1:5 dilutions. Cells were examined using a FACSAria flow cytometer and data analysis was performed by FloJo Software. The fluorescence intensity of 10,000 cells for each sample was quantified and results are expressed as mean fluorescence intensity (MFI), which reflects the cells surface density of the respective marker.
Endothelin-l (ET-l) secretion
HPAECs were seeded in a 24-well plate at a density of 10,000 cells per well for 24 h, after which the media was changed and the cells were allowed to grow for another 24 h. After a total of 48 h, the media was changed a second time and cells were incubated with either 25llg/ml of human recombinant CRP with 0.1% BSA, or with 0.1% BSA alone as control (eight wells per group). Supernatant was then collected and ET-I concentration was assessed using a commercial ELISA kit (ARP American Research Products Inc. Belmont, MA, USA). All determinations were performed in duplicate for all experiments.
Statistical analysis
All data are presented as mean ± SD for each experiment. Quantitative measurements of ET-I, ICAM-I and VCAM-I in different groups of HPAECs were compared by Student's t-Test. P values less than 0.05 were considered to be significant.
RESULTS

Effect of CRP on expression of adhesion molecules in HPAECs
Both IL-l~(positive control) and CRP induced significant cell surface expression of adhesion molecules. Compared to control, HPAECs, when treated for 24 hours with CRP, showed a ten-fold increase in the expression of ICAM-l (from 610 to 6553 mean fluorescence intensity, p < 0.005), and lA-fold increase in the expression of VCAM-l ( from 212 to 303 Mean Fluorescence Intensity, p < 0.03) (Figs. 1,2, and 3) .
Effect ofCRP on ET-l secretion from HPAECs
CRP potentiated the production of ET-l from Mean Fluo rescence intensity .g 20 HPAECs (Fig. 4) . The levels of ET-l secreted into the medium were significantly higher at 24 hours of CRP incubation compared to control, 46.54±18 vs 19.94±3 pg/ml, respectively (p < 0.05).
DISCUSSION
This study shows for the first time that human recombinant CRP induces dramatic upregulation of adhesion molecule ICAM-l and secretion ofET-l by human pulmonary artery endothelial cells. There was a lesser but still significant upregulation of adhesion molecule YCAM-l. This observed difference in the intensity of expression of the adhesion molecules on the HPAECs may be due to differential response of the endothelial cells from different organs to the above cytokines, secondary to varying numbers of surface receptors and regulation of YCAM-l gene transcription level (16, 17) . Results from the present study support a growing body of evidence suggesting that CRP exerts direct pro-inflammatory effects on endothelial cells (15) .
CRP as a prototypic marker of inflammation in numerous prospective studies predicts cardiovascular events (9, 10) . Several recent studies have now clearly demonstrated that human recombinant CRP at concentrations known to predict increased cardiovascular event rates, directly induces a proinflammatory, pro-thrombotic and pro-atherosclerotic phenotype in the systemic vasculature (8) . The pro-inflammatory effects include upregualtion of interleukin-6 (IL-6), adhesion molecules (ICAM and YCAM) (11, 15), chemokines (9), monocyte chemoattractant protein-l (MCP-l) and interleukin-S (IL-8). The pro-coagulant effects include inhibition of nitric oxide synthase (eNOS), prostacyclin, tPA and up-regulation of PAI(38).
In addition to cardiovascular diseases, inflammatory mechanisms play an important role in pulmonary diseases (1). Previous reports emphasize the role of inflammation in PAH. Indicators of inflammation and vascular damage such as highly sensitive C-reactive protein (hs CRP), the chemokines RANTES (regulated upon activation normal T-cell expressed and secreted), MCP-l and YCAM-l were found to be significantly elevated in patients with PAH compared to a control group of cardiovascular disease-free subjects (18) . In an in-vitro study of human pulmonary arterial tissue the combination of hypoxia with inflammatory mediators (IL-l, TNFalpha) caused a down regulation of the expression of endothelial nitric oxide synthase (eNOS), and increased transcription of ET-l, IL-6 and IL-8 (19) . Lung histology has shown inflammatory infiltrates in the form of plexiform lesions in patients displaying severe PAH, as well as increased expression of chemokines RANTES and fractalkines (1, 20) . In patients with systemic sclerosis-associated PAH the interaction between the endothelium and T cells via adhesion molecules has been well documented (21) . Some patients with severe PAH associated with systemic lupus erythematosus have experienced significant improvements with immunosuppressive therapy (22) . The frequent association of PAH and well-defined inflammatory conditions suggests a possible causal role of inflammation in vessel remodeling (1, 23) .
In patients with chronic obstructive pulmonary disease (COPD), increased pulmonary artery pressure was associated with higher levels of hs CRP and TNF-alpha (6) . An in-vitro study performed on lung resection specimens evaluating pulmonary arteries from patients with mild COPD, demonstrated a relationship between the intensity of inflammatory infiltrate, the intimal layer thickness and the impairment of the endothelium-dependent pulmonary artery relaxation (24) .
Although CRP is a robust marker of systemic inflammation, there is little consensus as to whether or not it is an effector molecule in pulmonary vascular disease or just an innocent bystander (6) . There is now strong evidence supporting the proinflammatory role of CRP in the atherosclerotic disease process. Studies have shown that endothelial cells from different organs have diverse responses to cytokines and lipopolysaccharide (LPS) (16, 25, 26) . To date, the effect of human recombinant CRP has only been studied on endothelial cells derived from systemic vasculature and not on HPAECs, hence those results cannot be unequivocally extrapolated to the pulmonary vasculature (10) . There have been no studies evaluating the role of human recombinant CRP on HPAECs. Our study extends these findings to the pulmonary vasculature.
Studies have shown that elevated levels ofCRP are associated with PAH and it is an important risk factor for pulmonary diseases. Our study demonstrated the direct pro-inflammatory effects of human recombinant CRP on HPAECs in vitro. CRP resulted in a significant increase in ET-l secretion, dramatic upregulation of ICAM-l expression and mild but significant upregulation ofVCAM-l expression. Our results suggest that the pro-inflammatory phenotype of CRP on pulmonary vasculature may contribute to the adverse outcome associated with higher levels of this acute-phase reactant.
Thus, lowering serum CRP levels and mitigating adhesion molecules expression and ET-l secretion may have beneficial effects. Statins appear to be potent drugs with a variety of pleotropic effects including vasculoprotective activity. Long-term treatment with statins is associated with reduction in serum CRP levels and better clinical outcome in patients with myocardial infarction (27) . Other studies on rats have shown a reduction in the synthesis of ET-l at the transcriptional level (28) , and attenuation of smoking-induced emphysema and PAH (29) . A recent study showed a significant increase in the exercise time and decrease in echocardiographically derived systolic PAP in patients with COPD and PAH when treated with the statin, pravastatin (30) .
Limitations
In this study endothelial cell medium supplemented with 10% fetal bovine serum was used as a culture medium for human pulmonary artery endothelial cells. We did not perform our experiment using serum-free medium as this had already been carried out in a prior experiment using human umbilical vein and coronary artery endothelial cells where they showed a negative result using serum-free medium. In our study, we demonstrated a pro-inflammatory effect of C-reactive protein on HPAECs. We intend to perform further experiments to elucidate the mechanisms and mediators behind this positive response of CRP on HPAECs.
In this study we demonstrate that human recombinant CRP induces expression of adhesion molecules and secretion of ET-l in HPAECs. The pro-inflammatory effects of CRP on HPAECs likely contributes to the pulmonary vascular remodeling seen in PAH. Further studies are needed to elucidate the basic mechanisms and mediators of pro-inflammatory effects of CRP on HPAECs.
If delineated and confirmed in vivo, these findings could potentially lead to new therapeutic targets for PAH.
